Your session is about to expire
← Back to Search
DxFLEX 10C Clinical Study
N/A
Waitlist Available
Research Sponsored by Beckman Coulter, Inc.
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial Must have
Timeline
Screening 3 weeks
Treatment Varies
Follow Up immediately after the analysis
Awards & highlights
No Placebo-Only Group
Summary
A multi-center method comparison study is designed per CLSI-EP09 A3. This study compares the qualitative immunophenotype agreement between DxFLEX and Navios EX to demonstrate the accuracy of the DxFLEX-10C system. A series of precision studies will be conducted with each focusing on different aspects of the DxFLEX-10C system.
Eligible Conditions
- Blood Cancers
Timeline
Screening ~ 3 weeks3 visits
Treatment ~ Varies
Follow Up ~ immediately after the analysis
Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~immediately after the analysis
Treatment Details
Study Objectives
Study objectives can provide a clearer picture of what you can expect from a treatment.Primary study objectives
Flow immunophenotyped normal and abnormal
Awards & Highlights
No Placebo-Only Group
All patients enrolled in this study will receive some form of active treatment.
Trial Design
2Treatment groups
Experimental Treatment
Group I: Hematologically normalExperimental Treatment1 Intervention
Based on immunophenotyping
Group II: Hematologically abnormalExperimental Treatment1 Intervention
Based on immunophenotyping
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
DxFLEX 10C
2022
N/A
~530
Find a Location
Who is running the clinical trial?
Beckman Coulter, Inc.Lead Sponsor
37 Previous Clinical Trials
443,258 Total Patients Enrolled
Guoyan Cheng, PhDStudy DirectorBeckman Coulter, Inc.